

# Contents

## Scientific Abstracts

### Welcome Address EULAR 2021 Abstracts Reviewers

#### Oral Presentations

OP0002	New perspectives on therapeutic immune tolerance .....	1
OP0003–OP0004	Autoimmune diseases by abnormal T cell function .....	1
OP0005	What the rheumatologist needs to know to interpret studies in 2021 .....	2
OP0006–OP0013	Opening Plenary Abstract session.....	2
OP0014–OP0021	Genomics, genetic basis of disease and functional genomics .....	8
OP0022–OP0029	Adaptive immunity (T cells and B cells) in rheumatic diseases and Innate immunity in rheumatic diseases.....	12
OP0030–OP0037	Of mice and man: insights into pathophysiology of rheumatoid arthritis and spondyloarthritis .....	16
OP0038–OP0045	Molecular mechanisms in Connective Tissue Disease.....	20
OP0046–OP0053	Clinical aspects of axial spondyloarthritis – science meets daily practice .....	24
OP0054–OP0061	Vasculitis - I .....	28
OP0062–OP0070	Vasculitis - II .....	33
OP0072–OP0073	New toys in rheumatology: single cell RNA and epigenetic sequencing, the holy grail? .....	38
OP0074–OP0081	Education .....	39
OP0083–OP0089	The origins of pain in RMDs .....	45
OP0090–OP0097	Infection-related rheumatic and orphan diseases.....	49
OP0098–OP0105	Rheumatoid arthritis - comorbidity and clinical aspects - I .....	54
OP0106–OP0113	Bone & Joints.....	59
OP0114–OP0120	Rheumatoid arthritis - biological DMARDs .....	63
OP0122–OP0128	Rheumatoid arthritis - non biologic treatment and small molecules .....	68
OP0129–OP0136	SLE, Sjögren's and APS - treatment and SLE, Sjögren's and APS - clinical aspects (other than treatment).....	74
OP0137–OP0144	Spondyloarthritis - treatment .....	80
OP0145–OP0152	Diagnostics and imaging procedures .....	86
OP0161–OP0168	Advances in Pediatric Rheumatology .....	97
OP0170–OP0177	Progress in myositis and scleroderma research - I .....	101
OP0178–OP0185	Rheumatoid arthritis - prognosis, predictors and outcome .....	106
OP0186–OP0187	Oncorheumatology: the crossroads of cancer and musculoskeletal diseases .....	112
OP0189–OP0190	Joint Session EULAR ESCM&I and EANM (European Association of Nuclear Medicine) – State-of-the-art nuclear imaging in RMDs.....	114
OP0193	Comorbidities in gout and hyperuricaemia .....	116
OP0194–OP0195	Immune events with checkpoint inhibitors .....	117
OP0196–OP0197	The aftermath of metabolic imbalance in OA .....	118
OP0199–OP0200	Emerging molecular targets in OA .....	120
OP0201	Origin and role of myeloid cells during homeostasis and inflammation .....	121
OP0202–OP0209	Crystal diseases .....	122
OP0210–OP0217	Rheumatoid arthritis - comorbidity and clinical aspects - II .....	126
OP0218–OP0225	Unrevealing the impact of PsA and comorbidity prevention.....	130
OP0226–OP0233	Psoriatic arthritis - treatment.....	136
OP0234–OP0241	Epidemiology and public health .....	144
OP0242–OP0249	Systemic sclerosis, myositis - etiology, pathogenesis and animal models .....	148
OP0250–OP0257	Imaging in axial spondyloarthritis – what is new?.....	152
OP0266–OP0273	Progress in myositis and scleroderma research - II.....	162
OP0281–OP0288	New Developments in COVID-Research .....	170
OP0289–OP0297	SLE, Sjögren's and APS - Clinical Aspects .....	177
OP0298–OP0299	Difficult to treat RA: definitions and mechanisms .....	183
OP0300	Quantitative imaging .....	184
OP0301	Let's consider Biologic Immunogenicity .....	185
OP0305–OP0306	Controversies on phenotypes in PsA.....	187
OP0307	Pharmacology and Microbiota.....	188
OP0308	What can we learn from the tissue .....	189

OP0309	EULAR Projects in musculoskeletal imaging .....	189
OP0310–OP0311	What's new: Latest advances in treatment and care in vasculitis and fibromyalgia .....	190
OP0312	Stress, inflammation & autoimmunity .....	191
OP0313–OP0314	Hyperinflammation and Covid19 .....	191
OP0315	Metabolic pathways during the regulation of inflammation and immunity.....	192
OP0316	Let's work. Together. ....	193
OP0318–OP0319	Deconditioning in rheumatic disease, time to recognise and tackle it .....	194
OP0320–OP0321	EFIS session: Emerging concepts how B cells drive systemic autoimmunity: from bench to clinic .....	196
<b>Late breaking abstracts</b>		
LB0001	.....	198
LB0002	.....	199
LB0003	.....	200
LB0004	.....	201
<b>Poster Tours</b>		
POS0001–POS0010	Adaptive immunity (T cells and B cells) in rheumatic diseases.....	203
POS0011–POS0020	Epidemiology and treatment of pain in RMDs .....	207
POS0021–POS0031	Epidemiology: Big Questions - Big studies.....	212
POS0032–POS0039	Imaging in axial spondyloarthritis .....	221
POS0040–POS0046	Molecular and structural changes of bone turnover during inflammatory disease .....	225
POS0047–POS0056	New Developments in COVID research.....	228
POS0067–POS0074	Pediatric Rheumatology – Basic and translational science .....	240
POS0075–POS0085	Pediatric Rheumatology - Clinical.....	244
POS0086–POS0092	Rheumatoid arthritis - non biologic treatment and small molecules - PART 1 .....	251
POS0093–POS0100	Rheumatoid arthritis - prognosis, predictors and outcome .....	256
POS0101–POS0111	SLE, Sjögren's and APS - clinical .....	260
POS0112–POS0121	Translating vasculitis .....	267
POS0122–POS0131	Central pain and other extra-articular associations to KOA .....	272
POS0132–POS0141	Crystal arthritis .....	277
POS0142–POS0151	Fine-tuning strategies (beyond treatments) to reduce the impact of PsA.....	282
POS0162–POS0171	Metabolic bone disease / Osteoporosis .....	293
POS0172–POS0180	Molecular profiles in connective tissue disease outcome.....	298
POS0181–POS0191	PROMs and markers.....	304
POS0192–POS0201	PsA treatment: what is new? .....	310
POS0202–POS0209	Rheumatoid arthritis - biological DMARDs .....	317
POS0210–POS0219	Rheumatoid Arthritis - comorbidity and clinical aspects - Part 1 .....	322
POS0220–POS0225	Rheumatoid arthritis - non biologic treatment and small molecules - PART 2 .....	328
POS0226–POS0235	Spondyloarthritis - treatment .....	332
POS0236–POS0245	Clinical aspects of spondyloarthritis.....	339
POS0246–POS0255	Clinical vasculitis.....	344
POS0256–POS0265	Diagnostics and imaging procedures .....	350
POS0276–POS0285	New drugs and therapies.....	362
POS0286–POS0295	Oncorheumatology .....	368
POS0296–POS0304	Public Health, Health Services and Health Economics .....	373
POS0305–POS0314	Rheumatoid Arthritis - comorbidity and clinical aspects - Part 2 .....	378
POS0315–POS0325	Scleroderma, myositis and related syndromes .....	383
POS0326–POS0335	Systemic sclerosis, myositis - etiology, pathogenesis and animal models.....	390
POS0336–POS0343	Vasculitis - Large vessel vasculitis.....	395
<b>POSTERS only</b>		
POS0344–POS0362	Genomics, genetic basis of disease and functional genomics .....	401
POS0363	Adaptive immunity (T cells and B cells) in rheumatic diseases.....	411
POS0364–POS0370	Innate immunity in rheumatic diseases .....	412
POS0371–POS0376	Osteo arthritis, aetiology, pathology and animal models.....	416
POS0377–POS0403	Rheumatoid arthritis - aetiology, pathogenesis and animal models .....	419
POS0404–POS0415	Spondyloarthritis - aetiology, pathogenesis and animal models.....	431
POS0416–POS0421	SLE, Sjögren's and APS - aetiology, pathogenesis and animal models.....	437
POS0422–POS0433	Systemic sclerosis, myositis and related syndromes - aetiology, pathogenesis and animal models.....	440
POS0434	Basic and translational pain science .....	445
POS0434–POS0504	Rheumatoid arthritis - prognosis, predictors and outcome .....	446

POS0505–POS0589	Rheumatoid arthritis - comorbidity and clinical aspects .....	485
POS0590–POS0645	Rheumatoid arthritis - biological DMARDs.....	527
POS0646–POS0679	Rheumatoid arthritis - non biologic treatment and small molecules .....	561
POS0680–POS0704	SLE, Sjögren's and APS – treatment .....	585
POS0705–POS0795	SLE, Sjögren's and APS - clinical aspects (other than treatment) .....	602
POS0796–POS0821	Vasculitis – large vessel vasculitis .....	650
POS0822–POS0831	Vasculitis – small vessel vasculitis.....	664
POS0832–POS0894	Scleroderma, myositis and related syndromes .....	669
POS0895–POS0941	Spondyloarthritis – treatment.....	704
POS0942–POS1019	Spondyloarthritis - clinical aspects (other than treatment) .....	734
POS1020–POS1058	Psoriatic arthritis – treatment .....	777
POS1059–POS1086	Psoriatic arthritis - clinical aspects (other than treatment) .....	808
POS1087–POS1119	Osteoarthritis .....	822
POS1120–POS1150	Crystal diseases, metabolic bone diseases other than osteoporosis.....	839
POS1151–POS1160	Infection-related rheumatic diseases.....	854
POS1161–POS1268	COVID-19 .....	858
POS1269–POS1291	Spine, mechanical musculoskeletal problems, local soft tissue disorders .....	919
POS1292–POS1334	Paediatric rheumatology.....	927
POS1335–POS1385	Other orphan diseases .....	949
POS1386–POS1410	Diagnostics and imaging procedures .....	976
POS1411–POS1417	Public health, health services research, and health economics .....	989
POS1418–POS1441	Epidemiology, risk factors for disease or disease progression.....	992
POS1442–POS1445	Validation of outcome measures and biomarkers.....	1005
POS1446–POS1447	Rehabilitation .....	1007
POS1448–POS1451	Education .....	1008
POS1452–POS1453	Educational cases .....	1010

## Publication Only

AB0001–AB0015	Genomics, genetic basis of disease and functional genomics .....	1036
AB0016–AB0028	Adaptive immunity (T cells and B cells) in rheumatic diseases.....	1042
AB0029–AB0034	Innate immunity in rheumatic diseases .....	1048
AB0035–AB0041	Osteo arthritis, aetiology, pathology and animal models.....	1050
AB0042–AB0069	Rheumatoid arthritis - aetiology, pathogenesis and animal models .....	1053
AB0070–AB0076	Spondyloarthritis - aetiology, pathogenesis and animal models.....	1065
AB0077–AB0088	SLE, Sjögren's and APS - aetiology, pathogenesis and animal models.....	1068
AB0089–AB0095	Systemic sclerosis, myositis and related syndromes - aetiology, pathogenesis and animal models.....	1074
AB0096–AB0098	Vasculitis - aetiology, pathogenesis and animal models .....	1076
AB0099–AB0150	Rheumatoid arthritis - prognosis, predictors and outcome .....	1078
AB0151–AB0194	Rheumatoid arthritis - comorbidity and clinical aspects .....	1103
AB0195–AB0246	Rheumatoid arthritis - biological DMARDs .....	1121
AB0247–AB0277	Rheumatoid arthritis - non biologic treatment and small molecules .....	1148
AB0278–AB0296	SLE, Sjögren's and APS – treatment .....	1165
AB0297–AB0351	SLE, Sjögren's and APS - clinical aspects (other than treatment) .....	1175
AB0352–AB0400	Vasculitis – small vessel vasculitis.....	1220
AB0401–AB0461	Scleroderma, myositis and related syndromes .....	1229
AB0462–AB0486	Spondyloarthritis – treatment.....	1257
AB0487–AB0520	Spondyloarthritis - clinical aspects (other than treatment) .....	1270
AB0521–AB0565	Psoriatic arthritis – treatment .....	1286
AB0566–AB0581	Psoriatic arthritis - clinical aspects (other than treatment) .....	1320
AB0582–AB0605	Osteoarthritis .....	1328
AB0606–AB0627	Osteoporosis .....	1339
AB0628–AB0646	Crystal diseases, metabolic bone diseases other than osteoporosis.....	1347
AB0647–AB0650	Infection-related rheumatic diseases .....	1356
AB0651–AB0712	COVID-19 .....	1358
AB0713–AB0719	Pain in rheumatic diseases, including fibromyalgia .....	1388
AB0720–AB0755	Paediatric rheumatology.....	1391
AB0756–AB0786	Other orphan diseases .....	1406
AB0787–AB0802	Diagnostics and imaging procedures .....	1419
AB0803–AB0811	Public health, health services research, and health economics .....	1426
AB0812–AB0833	Epidemiology, risk factors for disease or disease progression.....	1430
AB0834–AB0845	Validation of outcome measures and biomarkers .....	1441
AB0846–AB0852	Education .....	1446

AB0853–AB0858	Educational cases .....	1450
---------------	-------------------------	------

## Health Professionals in Rheumatology Abstracts

### **Oral Presentations**

OP0071-HPR	Like a gearwheel: HPR's research, education, and practice .....	38
OP0100-HPR	Rheumatoid arthritis - comorbidity and clinical aspects - I .....	55
OP0153-HPR–OP0160-HPR	HPR Abstract Session (I).....	92
OP0198-HPR	Monitoring and restoring health: Should we have a core set for multidisciplinary care in rheumatology .....	119
OP0258-HPR–OP0265-HPR	HPR Abstract Session (II) .....	157
OP0302-HPR	Context matters: Placebo and nocebo effects for pain management .....	185
OP0303-HPR	Myths and taboos around relationships: strategies for a sexy life .....	186
OP0322-HPR	[Joint session HPR/ PARE/ ARP] Mastering Self-management: State of art in a New Era ..	197

### **Poster Tours**

POS0152-HPR–POS0161-HPR	HPR - Adapting and individualising care.....	289
POS0266-HPR–POS0275-HPR	HPR - Understanding and measuring: expanding the toolbox .....	356

### **POSTERS only**

POS1454-HPR–POS1464-HPR	HPR Measuring health (development and measurement properties of PROs, tests, devices) .....	1011
POS1465-HPR–POS1469-HPR	HPR Epidemiology and public health (including prevention) .....	1017
POS1470-HPR–POS1473-HPR	HPR Interventions (educational, physical, social and psychological).....	1020
POS1474-HPR–POS1486-HPR	HPR Patients' perspectives, functioning and health (descriptive: qualitative or quantitative) .....	1022
POS1487-HPR–POS1489-HPR	HPR Service developments, innovation and economics in healthcare .....	1028
POS1490-HPR–POS1493-HPR	HPR Professional education, training and competencies.....	1029
POS1494-HPR–POS1496-HPR	HPR Interdisciplinary research .....	1031

### **Publication Only**

AB0859-HPR–AB0865-HPR	HPR Measuring health (development and measurement properties of PROs, tests, devices) .....	1453
AB0866-HPR–AB0871-HPR	HPR Epidemiology and public health (including prevention) .....	1456
AB0872-HPR–AB0883-HPR	HPR Interventions (educational, physical, social and psychological).....	1459
AB0884-HPR–AB0902-HPR	HPR Patients' perspectives, functioning and health (descriptive: qualitative or quantitative) .....	1465
AB0903-HPR–AB0909-HPR	HPR Service developments, innovation and economics in healthcare .....	1474
AB0910-HPR–AB0911-HPR	HPR Professional education, training and competencies.....	1477
AB0912-HPR	HPR Interdisciplinary research .....	1478

## People with Arthritis and Rheumatism in Europe Abstracts

### **Oral Presentations**

OP0009-PARE	Opening Plenary Abstract session.....	5
OP0082-PARE	Challenges for Patients and Patients' Organisations in Times of the Pandemic .....	44
OP0169-PARE	Challenges for working people with RMDs in pandemic times .....	101
OP0191-PARE	Improving collaborative research and patients' participation in health decision-making .....	115
OP0274-PARE–OP0280-PARE	PARE Abstract session .....	166
OP0304-PARE	Myths and taboos around relationships: strategies for a sexy life .....	187
OP0317-PARE	Let's work. Together. .....	193
OP0323-PARE–OP0324-PARE	Members and Volunteers – Unknown beings? How to explore their interests, establish contacts and support.....	197

### **Poster Tours**

POS0057-PARE–POS0066-PARE	PARE Poster Tour.....	235
---------------------------	-----------------------	-----

### **POSTERS only**

POS1497-PARE	Patient information and education .....	1033
POS1498-PARE	Building patient led organisations.....	1033
POS1499-PARE	Arthritis research.....	1034

**Publication Only**

AB0913-PARE–AB0922-PARE	Patient information and education.....	1478
AB0923-PARE	Building patient led organisations.....	1482
AB0924-PARE–AB0925-PARE	Arthritis research.....	1483
AB0926-PARE	Psychosocial support .....	1484
AB0927-PARE	Work and rehabilitation .....	1484
<b>Author Index</b> .....		1486